A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
Phase: PHASE3
Conditions: Alagille Syndrome
Sponsor: Albireo

PPD

PPD

PPD
PPD
PPD
PPD

CCI
CCI
CCI
CCI
CCI
CC
I
CCI
CCI

CCI

CCI

CCI